Protara Therapeutics (TARA) Long-Term Deferred Tax (2013 - 2023)

Protara Therapeutics' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $1.6 million for Q4 2023.

• In Q4 2023, Long-Term Deferred Tax fell 96.12% year-over-year to $1.6 million; the TTM figure through Dec 2023 stood at $1.6 million (down 96.12% YoY), while the FY2023 annual figure was $1.6 million, down 96.12% from the prior year.
• Long-Term Deferred Tax was $1.6 million for Q4 2023 at Protara Therapeutics, down from $40.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $40.5 million in Q4 2022 to a low of $2000.0 in Q4 2019.
• Historically, Long-Term Deferred Tax has averaged $8.8 million across 5 years, with a median of $1.5 million in 2021.
• The sharpest annual moves came in 2020 and 2023: Long-Term Deferred Tax soared 16000.0% in 2020, then plunged 96.12% in 2023.
• A 5-year view of Long-Term Deferred Tax shows it stood at $2000.0 in 2019, then jumped by 16000.0% to $322000.0 in 2020, then jumped by 381.06% to $1.5 million in 2021, then surged by 2512.07% to $40.5 million in 2022, then slumped by 96.12% to $1.6 million in 2023.
• The last three Long-Term Deferred Tax figures came in at $1.6 million (Q4 2023), $40.5 million (Q4 2022), and $1.5 million (Q4 2021), per Business Quant data.